Literature DB >> 23345580

Blueprints of signaling interactions between pattern recognition receptors: implications for the design of vaccine adjuvants.

Kim Timmermans1, Theo S Plantinga, Matthijs Kox, Michiel Vaneker, Gert Jan Scheffer, Gosse J Adema, Leo A B Joosten, Mihai G Netea.   

Abstract

Innate immunity activation largely depends on recognition of microorganism structures by Pattern Recognition Receptors (PRRs). PRR downstream signaling results in production of pro- and anti-inflammatory cytokines and other mediators. Moreover, PRR engagement in antigen-presenting cells initiates the activation of adaptive immunity. Recent reports suggest that for the activation of innate immune responses and initiation of adaptive immunity, synergistic effects between two or more PRRs are necessary. No systematic analysis of the interaction between the major PRR pathways were performed to date. In this study, a systematical analysis of the interactions between PRR signaling pathways was performed. PBMCs derived from 10 healthy volunteers were stimulated with either a single PRR ligand or a combination of two PRR ligands. Known ligands for the major PRR families were used: Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and RigI-helicases. After 24 h of incubation, production of tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), IL-6, and IL-10 was measured in supernatants by enzyme-linked immunosorbent assay (ELISA). The consistency of the PRR interactions (both inhibitory and synergistic) between the various individuals was assessed. A number of PRR-dependent signaling interactions were found to be consistent, both between individuals and with regard to multiple cytokines. The combinations of TLR2 and NOD2, TLR5 and NOD2, TLR5 and TLR3, and TLR5 and TLR9 acted as synergistic combinations. Surprisingly, inhibitory interactions between TLR4 and TLR2, TLR4 and Dectin-1, and TLR2 and TLR9 as well as TLR3 and TLR2 were observed. These consistent signaling interactions between PRR combinations may represent promising targets for immunomodulation and vaccine adjuvant development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345580      PMCID: PMC3592350          DOI: 10.1128/CVI.00703-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

1.  GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation.

Authors:  Matthijs Kox; Jeroen F van Velzen; Jan C Pompe; Cornelia W Hoedemaekers; Johannes G van der Hoeven; Peter Pickkers
Journal:  Biochem Pharmacol       Date:  2009-07-01       Impact factor: 5.858

2.  Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines.

Authors:  Qing Zhu; Colt Egelston; Aravindhan Vivekanandhan; Satoshi Uematsu; Shizuo Akira; Dennis M Klinman; Igor M Belyakov; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-09       Impact factor: 11.205

Review 3.  Toll-like receptors and innate immunity.

Authors:  Himanshu Kumar; Taro Kawai; Shizuo Akira
Journal:  Biochem Biophys Res Commun       Date:  2009-08-15       Impact factor: 3.575

Review 4.  Dusting the sugar fingerprint: C-type lectin signaling in adaptive immunity.

Authors:  Jeroen den Dunnen; Sonja I Gringhuis; Teunis B H Geijtenbeek
Journal:  Immunol Lett       Date:  2009-10-04       Impact factor: 3.685

Review 5.  Biology of interleukin-10.

Authors:  Robert Sabat; Gerald Grütz; Katarzyna Warszawska; Stefan Kirsch; Ellen Witte; Kerstin Wolk; Jens Geginat
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-05       Impact factor: 7.638

Review 6.  Toll-like receptors and their role in gastrointestinal disease.

Authors:  Adam G Testro; Kumar Visvanathan
Journal:  J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 4.029

7.  Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.

Authors:  Young Ok Jung; Mi-La Cho; Seon-Yeong Lee; Hye-Jwa Oh; Jin-Sil Park; Mi-Kyung Park; Min-Jung Park; Ji-Hyeon Ju; Sung-Il Kim; Sung-Hwan Park; Ho-Youn Kim; Jun-Ki Min
Journal:  Immunol Lett       Date:  2009-03-21       Impact factor: 3.685

8.  Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages.

Authors:  Gerben Ferwerda; Friederike Meyer-Wentrup; Bart-Jan Kullberg; Mihai G Netea; Gosse J Adema
Journal:  Cell Microbiol       Date:  2008-06-28       Impact factor: 3.715

9.  Identification of novel transcriptional regulators involved in macrophage differentiation and activation in U937 cells.

Authors:  Young-Sook Baek; Stefan Haas; Holger Hackstein; Gregor Bein; Maria Hernandez-Santana; Hans Lehrach; Sascha Sauer; Harald Seitz
Journal:  BMC Immunol       Date:  2009-04-02       Impact factor: 3.615

Review 10.  [Role of toll-like receptors in respiratory diseases].

Authors:  Astrid Crespo-Lessmann; Cándido Juárez-Rubio; Vicente Plaza-Moral
Journal:  Arch Bronconeumol       Date:  2009-09-17       Impact factor: 4.872

View more
  15 in total

1.  Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

Authors:  Janine K Tom; Rock J Mancini; Aaron P Esser-Kahn
Journal:  Chem Commun (Camb)       Date:  2013-10-25       Impact factor: 6.222

2.  A cell-based microarray to investigate combinatorial effects of microparticle-encapsulated adjuvants on dendritic cell activation.

Authors:  Abhinav P Acharya; Matthew R Carstens; Jamal S Lewis; Natalia Dolgova; C Q Xia; Michael J Clare-Salzler; Benjamin G Keselowsky
Journal:  J Mater Chem B       Date:  2015-09-30       Impact factor: 6.331

3.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

4.  The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan.

Authors:  Kenneth Quayle; Catherine Coy; Leanna Standish; Hailing Lu
Journal:  J Nat Med       Date:  2014-12-16       Impact factor: 2.343

5.  A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.

Authors:  Jason Gummow; Yanrui Li; Wenbo Yu; Tamsin Garrod; Danushka Wijesundara; Amelia J Brennan; Ranajoy Mullick; Ilia Voskoboinik; Branka Grubor-Bauk; Eric J Gowans
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

6.  Macrophages polarization is mediated by the combination of PRR ligands and distinct inflammatory cytokines.

Authors:  Lili Zhou; Xixi Cao; Jie Fang; Yuhong Li; Mingwen Fan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 7.  Directing the immune system with chemical compounds.

Authors:  Rock J Mancini; Lalisa Stutts; Keun Ah Ryu; Janine K Tom; Aaron P Esser-Kahn
Journal:  ACS Chem Biol       Date:  2014-04-30       Impact factor: 5.100

Review 8.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10

9.  Differences in innate cytokine responses between European and African children.

Authors:  Lucja A Labuda; Sanne E de Jong; Lynn Meurs; Abena S Amoah; Moustapha Mbow; Ulysse Ateba-Ngoa; Alwin J van der Ham; André C Knulst; Maria Yazdanbakhsh; Ayola A Adegnika
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  Targeted Programming of the Lymph Node Environment Causes Evolution of Local and Systemic Immunity.

Authors:  James I Andorko; Joshua M Gammon; Lisa H Tostanoski; Qin Zeng; Christopher M Jewell
Journal:  Cell Mol Bioeng       Date:  2016-06-27       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.